Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: juvenile idiopathic arthritis

What’s the Role of Epstein-Barr Virus Reactivation in Lupus Development?

Larry Beresford   |  November 12, 2020

A strong association between Epstein-Barr virus (EBV) infections and systemic lupus erythematosus (SLE) has been known since the 1970s. Although the etiology of SLE is not fully established, multiple genetic factors and polymorphisms in genes involved in the immune system have been implicated, with environmental factors also contributing to the development of this complex condition….

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Epstein-Barr virus (EBV)

The 2020 ACR Awards of Distinction & Masters Class

Linda Childers  |  November 12, 2020

Presidential Gold Medal The highest award the ACR can bestow, the Presidential Gold Medal is awarded in recognition of outstanding achievements in rheumatology over an entire career. This year’s award went to James O’Dell, MD, the Stokes-Shackleford Professor of Internal Medicine, vice chair of internal medicine and chief of the Division of Rheumatology at the…

Filed under:Awards Tagged with:ACR Convergence 2020Ciarán M. DuffyDr. Abby AbelsonDr. Ami Aalok ShahDr. Andras PerlDr. Angela TincaniDr. Bernardo A. Pons-EstelDr. Brian F. MandellDr. Carlos J. LozadaDr. Daniel SolomonDr. Edward K.L. ChanDr. Emily IsaacsDr. James O’DellDr. James R. SeiboldDr. James WitterDr. Joanne M. JordanDr. Kara PetersenDr. Kathleen M. O’NeilDr. Leonard H. SigalDr. M. Virginia PascualDr. Martin Jan BergmanDr. Michael B. BrennerDr. Nancy E. LaneDr. Norman T. IlowiteDr. Pamela WeissDr. Pierre MiossecDr. Robert W. WarrenDr. Sheldon SolomonDr. Stuart Kassan

Ethics Forum: The Ethical Considerations of Prior Authorization

Christina Schutt, DO, FAAP  |  September 17, 2020

The mother of a 15-year-old patient with juvenile idiopathic arthritis/enthesitis-related arthritis (JIA/ERA) called the office in tears. She said she was having an insurance problem. Her son had been a star track athlete when he developed severe back pain. Magnetic resonance imaging showed evidence of severe sacroiliitis. He was started on a tumor necrosis factor…

Filed under:EthicsInsurance Tagged with:EthicsEthics Foruminsuranceprior authorization

FDA Approves Canakinumab for Adult-Onset Still’s Disease

Michele B. Kaufman, PharmD, BCGP  |  July 14, 2020

Canakinumab, an interleukin (IL) 1 blocker, can now be prescribed to treat patients with active Still’s disease and adult-onset Still’s disease (AOSD)…

Filed under:ConditionsDrug UpdatesOther Rheumatic Conditions Tagged with:adult Still's DiseasecanakinumabFDAU.S. Food and Drug Administration (FDA)

Respiratory Failure More Common in COVID-19 Patients with Rheumatic Disease

Marilynn Larkin  |  June 23, 2020

NEW YORK (Reuters Health)—COVID-19-infected patients with rheumatic disease were more likely to experience respiratory failure than those without rheumatic disease, according to a retrospective study in China. “Immune dysregulation underlying rheumatic diseases may affect the disease manifestation of COVID-19,” Dr. Jixin Zhong of Huazhong University of Science and Technology, Wuhan, tells Reuters Health by email….

Filed under:Uncategorized Tagged with:coronavirusCOVID-19respiratoryRheumatic Disease

Diagnosing & Treating Hemophagocytic Lymphohistiocytosis in Adults

Srujana Pachigolla, MD, & Adegbenga Bankole, MD  |  June 15, 2020

Primary hemophagocytic lymphohistiocytosis (HLH) is caused by genetic mutations and inherited syndromes; it therefore occurs in the pediatric age group. Secondary HLH, however, is more common in adults and is often triggered by other disease states, such as malignancies, chronic immuno­suppression, infections and autoimmune disease.1,2 Macrophage activation syndrome (MAS) is a subset of secondary HLH…

Filed under:ConditionsVasculitis Tagged with:case reporthemophagocytic lymphohistiocytosishemophagocytic lymphohistiocytosis (HLH)HLHmacrophage activation syndrome

2 Pediatric Indications Sought for Golimumab

Michele B. Kaufman, PharmD, BCGP  |  June 3, 2020

The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…

Filed under:Drug Updates Tagged with:FDAGolimumabjuvenile idiopathic arthritis (JIA)Psoriatic ArthritisU.S. Food and Drug Administration (FDA)

Some Telemedicine Barriers Are Down During COVID-19 Pandemic

Larry Beresford  |  May 15, 2020

Telerheumatology—which refers to the application of electronic communication technology to clinical encounters from a distance between rheumatologists and their patients—has the potential to extend a workforce projected to experience significant shortfalls, making it more accessible to more patients. Multiple barriers that stood in the way of taking full advantage of this promise are now down—at…

Filed under:Practice SupportTechnology Tagged with:Centers for Medicare & Medicaid Services (CMS)telemedicinetelerheumatology

3 Ways to Advance the Med-Peds Role in Rheumatology

Carina Stanton  |  April 27, 2020

Research into training and careers for Med-Peds—internal medicine-pediatrics trained rheumatologists–will help pinpoint how this unique specialty can support patient needs and address rheumatology workforce shortages…

Filed under:Career DevelopmentEducation & TrainingProfessional Topics Tagged with:adult rheumatologistCareerMed-Pedspediatric rheumatologist

Local Depletion of Resident Memory T Cells May Reduce Site-Specific Joint Flares

Carina Stanton  |  April 21, 2020

A study found resident memory T cells may mediate inflammatory arthritis and trigger flares in specific joints, suggesting local depletion of these cells could be a therapeutic strategy…

Filed under:ConditionsRheumatoid Arthritis Tagged with:2019 ACR/ARP Annual MeetingFlaresjointjuvenile idiopathic arthritis (JIA)Rheumatoid Arthritis (RA)

  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 37
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences